Comparative Study Of The Effectiveness Of Vedolizumab Versus Ustekinumab After Anti-Tnf Failure In Crohn's Disease (Versus-Cd): Data From Eneida Registry.
María José GarcíaMontserrat RiveroAgnès Fernández-ClotetRuth de FranciscoBeatriz SiciliaFrancisco Mesonero GismeroMaría Luisa de CastroMaría José CasanovaFederico BertolettiFrancisco Javier García-AlonsoAlicia López-GarcíaRaquel VicenteXavier CalvetManuel Barreiro-de AcostaJuan Ferrer RosiquePilar Varela TrastoyAlejandro NuñezElena RicartSabino RiestraLara Arias GarcíaMaría RodríguezLaura ArranzRamón PajaresRaquel MenaMargalida CalafatPatricia CamoFernando BermejoÁngel PonferradaRosa Eva MadrigalJordina LlaóEva SeséEugenia SánchezJuan Ramón Pineda MariñoCarlos González MuñozaAna Yaiza Carbajo LópezAna Belén JuliánAlbert Villoria FerrerIria Baston-ReyLorena JaraPedro AlmelaLaura CodesidoSaioa de la MazaCarles LealBerta CaballolIsabel Pérez-MartínezRaquel Vinuesa CampoJavier CrespoEugeni DomènechMaría ChaparroFrancisco Javier García-Alonsonull nullPublished in: Journal of Crohn's & colitis (2023)
In CD patients who have failed to anti-TNF agents, ustekinumab seems to be superior to vedolizumab in terms of durability and effectiveness in clinical practice. The safety profile is good and similar for both treatments.
Keyphrases
- randomized controlled trial
- end stage renal disease
- rheumatoid arthritis
- clinical practice
- systematic review
- newly diagnosed
- chronic kidney disease
- ulcerative colitis
- patients with inflammatory bowel disease
- peritoneal dialysis
- electronic health record
- nk cells
- machine learning
- deep learning
- artificial intelligence
- data analysis